Interview 3 Mar 2021 The Promises of CRISPR Genome Editing in Biomedicine Tony Ho, Head of Research and Development at CRISPR Therapeutics, offers his insights into the advantages of CRISPR gene editing over other technologies and what the future holds for the genome editing field. For decades, gene editing required engineering DNA-cutting enzymes, such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), for every specific […] March 3, 2021 - 5 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
Sponsored by Merck 2 Mar 2021 How is Bioprocessing 4.0 Revolutionizing Biomanufacturing? The digital transformation of biopharmaceutical process development is known as Bioprocessing 4.0. Using the internet of things, digital biomanufacturing creates a network of data sources, materials, equipment, and industry representatives. This creates a competitive advantage, increases productivity, and boosts the value of biomanufacturing. We have spoken to Merrilee Whitney, Head of the BioContinuum™ platform at Merck* […] March 2, 2021 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 1 Mar 2021 How Are European Biotechs Tackling the Cardiovascular Disease Problem? Cardiovascular diseases may not regularly grab the headlines, but they’re the leading cause of mortality globally, making up over 30% of all deaths worldwide. While there are many established treatments on the market, there’s still a need for more effective treatments – can biotech companies provide the answer? We all know that frequent exercise, a […] March 1, 2021 - 9 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 25 Feb 2021 Legal Fights Accompany Big Fundraises in Liquid Biopsy Scene A recent patent fight between the liquid biopsy companies Natera and Inivata is only the latest of many spats over DNA sequencing technology that could potentially revolutionize the detection and treatment of cancer. Earlier this month, the UK-US biotech Inivata raised €29M in the second closing of a Series C round. The company will use […] February 25, 2021 - 5 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2021 European Cancer Deals Increasingly Focus on Natural Killer Cells Natural killer cells are becoming a hot topic in the booming cancer cell therapy scene, with the field’s latest big deal being a €640M licensing agreement between the French biotech Cellectis and US company Cytovia. T-cell immunotherapies like CAR T-cell therapy have revolutionized cancer treatment in recent times. However, they have a significant disadvantage. The […] February 23, 2021 - 6 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email
Interview 22 Feb 2021 How Automation Can Augment Drug Discovery Research Robotics and artificial intelligence are rapidly changing the way we discover drugs. Martin-Immanuel Bittner, CEO and co-founder of Arctoris, discusses the benefits and challenges of introducing automation in drug discovery efforts. The Oxford-based startup Arctoris was established in 2016 with the objective of offering remote access to automated drug discovery. At a time when researchers […] February 22, 2021 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 18 Feb 2021 Cannabinoids in Focus after GW Pharmaceuticals Snapped up for €6B This month’s €6B acquisition of the UK heavyweight GW Pharmaceuticals by Jazz Pharmaceuticals has been hailed as a major validation of the medical cannabinoid industry. The deal is the largest to date in the medical cannabinoid field. Jazz’s offer valued GW’s shares nearly 50% higher than their previous day’s close. The acquisition is expected to […] February 18, 2021 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2021 Cancer Research UK Cuts Two Biotech Collaborations Amid Pandemic Squeeze The major research funder CRUK and two of the biotech companies it works with have decided to cut development ties as the financial impact of the coronavirus disease pandemic continues to bite. Cancer Research UK (CRUK) is a prolific research charity, running a multitude of collaborations with academics and biotech companies around the world. However, […] February 16, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Feb 2021 Top Neurotech Startups Unlocking the Brain in Russia Russia has established itself as a hub for neurotech startups, attracting scientists and business people keen to understand, treat, and repair the human brain. Here are the startups leading the charge of neurotech innovation in Russia. Neurotechnology is a field of research that aims to read and influence the brain. Turns out that neurotech is […] February 10, 2021 - 6 minutesmins - By Carlos de Rojas Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2021 Oxford’s Covid-19 Vaccine Blazes Trail for Oncolytic Virus Firms Since the debut of Imlygic in 2015, no other oncolytic virus cancer therapies have been approved by the FDA and EMA. However, we’re seeing the first signs that the Covid-19 pandemic may help the field get out of the rut. Earlier this month, the Oxford-based firm Theolytics raised €5.6M in a Series A round. This […] January 26, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2020 Covid-19 Leaves Lasting Impact on Hematology at ASH 2020 Conference Under the heavy shadow of the Covid-19 pandemic, last week’s annual conference of the American Society of Hematology (ASH) displayed the achievements of many innovative treatments for blood conditions, including gene and cell therapies. A sweeping new wave of Covid-19 infections that is forcing new lockdowns across the northern hemisphere is already reshaping the biotech […] December 17, 2020 - 6 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2020 SynOx Joins Wave of Biotechs Attacking Solid Tumor ‘Comfort Zone’ The newly founded SynOx has become the latest startup to attack solid tumors via their ‘comfort zone’, known as the tumor microenvironment. SynOx was spun out of the UK firm Celleron Therapeutics last week with a huge Series A round of €37M. The fledgling company is developing an antibody drug that Celleron licensed from Roche […] November 23, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email